A Phase 2 interventional study of empagliflozin in cystic fibrosis-related diabetes
Active, Not Recruiting Phase 2,Phase 3 NCT06149793
Study Description
A study to evaluate the safety and effectiveness of empagliflozin in overweight/obese adults with cystic fibrosis-related diabetes
Study Details
- Registry ID:
- NCT06149793
- Conditions:
- Cystic Fibrosis-related Diabetes, Cystic Fibrosis
- Phase:
- Phase 2,Phase 3
- Target Enrollment:
- 8 participants
- Start Date:
- Age Range:
- 18–999 years
- Healthy Volunteers:
- No
Study Locations (1 site)
-
University of Minnesota
Minneapolis, Minnesota, United States
Interested in Participating?
Check your eligibility and learn more about this study on TrialScreen.